mGluR4 (Metabotropic Glutamate Receptor 4) is a Group III metabotropic glutamate receptor that serves primarily as a presynaptic autoreceptor, modulating glutamate release throughout the central nervous system. mGluR4 is a particularly promising target for Parkinson's disease therapy due to its expression in the basal ganglia and its modulatory effects on motor control.
| Property |
Value |
| Protein Name |
Metabotropic Glutamate Receptor 4 |
| Gene Symbol |
GRM4 |
| UniProt ID |
Q14833 |
| Molecular Weight |
102 kDa (912 aa) |
| Structure |
Class C GPCR: VFT, cysteine-rich, 7-TM domains |
| Expression |
Brain (cerebellum, basal ganglia, hippocampus), peripheral tissues |
| Subcellular Localization |
Presynaptic terminals, dendritic shafts, postsynaptic density |
mGluR4 exhibits the characteristic Class C GPCR architecture:
¶ Extracellular Domains
- Venus Fly Trap (VFT) Domain: Large extracellular glutamate-binding domain with low affinity for glutamate
- Cysteine-Rich Domain (CRD): Essential for receptor dimerization and signal transduction
¶ Transmembrane Domains
- 7-TM Domain: Seven transmembrane helices forming the canonical GPCR bundle
- Conserved Motifs: Sequence motifs typical of class C receptors
¶ Intracellular Domains
- C-terminal Tail: Intracellular tail containing motifs for receptor trafficking and protein interactions
The mGluR4 homodimer is the functional unit, with each protomer capable of binding ligand and transducing signals.
¶ Motor Control and Cerebellar Function
mGluR4 plays critical roles in motor control:
- Cerebellar Function: Highly expressed in cerebellar Purkinje cells, essential for motor learning
- Basal Ganglia Modulation: Regulates output from the basal ganglia
- Motor Coordination: Critical for coordinated movement
- Sensorimotor Integration: Integrates sensory information for movement
As a presynaptic autoreceptor:
- Inhibits Glutamate Release: Reduces glutamate from presynaptic terminals
- Modulates GABA Release: Alters GABAergic signaling
- Self-regulation: Provides feedback control of glutamatergic transmission
- Homeostatic Plasticity: Maintains synaptic homeostasis
mGluR4 activation provides neuroprotective effects:
- cAMP Modulation: Reduces cAMP accumulation, limiting excitotoxic signaling
- PI3K/Akt Activation: Activates pro-survival pathways
- Anti-inflammatory Effects: Modulates microglial activation
- Modulates LTD in the cerebellum
- Regulates synaptic strength in various brain regions
- Involved in learning and memory processes
mGluR4 is a major therapeutic target for PD:
- Basal Ganglia Expression: High expression in the substantia nigra pars reticulata (SNr) and globus pallidus externus (GPe)
- Motor Symptom Relief: mGluR4 agonists reduce parkinsonian motor symptoms in animal models
- Dopaminergic Protection: May protect dopaminergic neurons from degeneration
- L-DOPA-induced Dyskinesias: mGluR4 modulation may reduce dyskinesias with PHCCC and related compounds showing efficacy
Clinical Potential: Positive allosteric modulators (PAMs) of mGluR4 are being developed for PD treatment.
mGluR4 has emerging roles in AD:
- Synaptic Dysfunction: Altered mGluR4 signaling in hippocampal circuits
- Cognitive Decline: Modulators show cognitive enhancement potential
- Neuroprotection: mGluR4 activation protects against amyloid toxicity
- Motor Neuron Expression: mGluR4 expressed on motor neurons
- Altered Signaling: Dysregulated in ALS models
- Neuroprotective Potential: mGluR4 activation may protect motor neurons
- Basal Ganglia Dysfunction: Altered mGluR4 signaling in striatum
- Motor Symptoms: May contribute to chorea and other motor symptoms
- Therapeutic Potential: Being investigated as a target
- Anticonvulsant Effects: mGluR4 agonists show anticonvulsant properties in seizure models
- Aberrant Plasticity: Dysregulated mGluR4 signaling may contribute to epileptogenesis
- Therapeutic Target: mGluR4 PAMs being explored for seizure control
mGluR4 primarily couples to Gi/o proteins, activating:
- Inhibition of Adenylate Cyclase: Reduces cAMP production
- Activation of GIRK Channels: Hyperpolarizes neurons
- PI3K/Akt Pathway: Pro-survival signaling
- ERK/MAPK Pathway: Gene expression regulation
- Modulation of Voltage-gated Calcium Channels: Reduces calcium influx
| Approach |
Mechanism |
Development Stage |
Examples |
| mGluR4 PAMs |
Enhance receptor activity |
Preclinical |
PHCCC, LSP1-1, VU0415374 |
| mGluR4 Agonists |
Direct activation |
Preclinical |
L-AP4 |
| Gene Therapy |
Increase expression |
Preclinical |
AAV-GRM4 |
| Symptomatic Relief |
Motor symptom reduction |
Clinical Trials |
- |
- mGluR4 PAMs have been in preclinical development for PD
- PHCCC showed efficacy in parkinsonian models
- No mGluR4-selective compounds in clinical trials yet
Recent advances include brain-penetrant mGluR4 PAMs with improved pharmacokinetic properties:
- VU0415374: First-in-class brain-penetrant mGluR4 PAM
- LSP1-1: Shows efficacy in non-human primates
- ABP-101: Advanced preclinical candidate
- GRM4 Knockout Mice: Show enhanced motor activity, altered cerebellar function
- Transgenic Overexpression: Protects against MPTP-induced parkinsonism
- Viral Vector Delivery: AAV-mGluR4 improves motor function in PD models
- GRM4 expression in peripheral blood cells
- CSF mGluR4 as potential biomarker
- Genetic variants for patient stratification
Current research focuses on:
- Developing brain-penetrant mGluR4 PAMs for clinical use
- Understanding mGluR4 heteromer pharmacology
- Gene therapy approaches for PD
- Combination therapies with dopaminergic drugs
- Biomarker development for patient selection
Expression data for GRM4 in the human brain can be explored through the following Allen Brain Atlas resources: